Lantern Pharma Reports Clinical Data for LP-300

Lantern Pharma reported clinical data and updates in the form of a presentation from its ongoing Phase 2 Harmonic trial evaluating LP-300 in combination with carboplatin and pemetrexed in patients with EGFR Exon 21 L858R-mutant non-small cell lung cancer, NSCLC, who have progressed following TKI-based therapy. The emerging dataset reveals a pattern: the progression-free survival benefit of LP-300 deepens with treatment duration, and the signal is most pronounced in the L858R subgroup - a molecularly defined population with a poor prognosis and limited options following frontline TKI therapy. Key highlights: PFS benefit deepens with treatment duration: L858R patients treated through up to six cycles of LP-300 reached an 8.9-month median PFS, versus 8.4 months overall - future patients will be eligible to receive up to 8 doses of LP-300. Durable, deep responses: tumor reduction in over 70% of evaluable L858R patients, responses beyond two years, and a 77% clinical benefit rate. Clean, treatment-enabling safety: no clinically meaningful toxicity beyond chemotherapy, comparing favorably with amivantamab plus chemotherapy on a cross-trial basis.